Biomodels is a pre-clinical drug development company with thirteen years experience helping biotechnology and pharmaceutical companies demonstrate the efficacy of novel drug substances in relevant animal models. We specialize in non-GLP studies to demonstrate efficacy and define mechanism of action, allowing clients to expedite the drug development process. Our studies enable clients to move lead compounds into clinical development by demonstrating efficacy and elucidating mechanism of action in the most appropriate and relevant small animal models.

Over the years Biomodels core competencies in cancer supportive care, oncology and inflammation have expanded to include a range a broad spectrum of disease indications and essential pharmacology. Biomodels leverages its access to clinical and scientific thought leaders, along with experienced and knowledgeable staff has to rapidly select appropriate models or develop custom models if necessarty. The results are preclinical data that are meaningfully translatable to the clinic, a dramatic decrease in the amount of time spent conducting preclinical studies, and added confidence in the design of clinical studies, all of which conveys substantial cost savings.

The “Biomodels Advantage” is best seen in our unique Service Model. Forming the base of this model is our extensive industry- and clinically relevant expertise and experience. Combined with customized solution , unmatched personalized service and rapid turnaround, the result is a wide array of features and benefits that set Biomodels apart from other organizations.